Editas Medicine, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 49.04 million compared to USD 50.52 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 0.74 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.575 USD | -0.80% | -2.10% | -44.82% |
05-14 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
05-09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.82% | 462M | |
+42.91% | 50.93B | |
-0.43% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.10% | 26.02B | |
-21.89% | 18.9B | |
+7.82% | 13.21B | |
+24.07% | 12.17B | |
+30.39% | 12.16B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023